Anti-HLA antibodies in heart transplantation
Anti-HLA antibodies in heart transplantation
复制标题
DOI：
10.1016/j.trim.2003.08.002
复制
发表时间：
2004-01-01
影响因子：
1.5
通讯作者：
Mancini, D
中科院分区：
文献类型：
--
作者：
Vasilescu, ER;Ho, EK;Mancini, D
我们分析了移植相关冠状动脉疾病(TRCAD)的发展与下列潜在危险因素之间的关系：(A)受体和供者之间的人类白细胞抗原不匹配的数量；(B)抗人类白细胞抗原抗体的产生；(C)淋巴细胞渗入移植物的生长；以及(D)活检证实的急性排斥反应的发生频率。研究人群包括285名成年同种异体心脏移植受者，他们接受了两年或更长时间的监测。结果表明，在含有IL-2的介质中，TRCAD、抗HLAII类抗体的产生和移植物中淋巴细胞的体外增殖能力之间存在显著的相关性。移植物表达的针对HLA-DR抗原的体液和细胞免疫反应似乎是TRCAD发生的基础。(C)2003爱思唯尔B.V.保留所有权利。
We have analyzed the relationship between the development of transplant-related coronary artery disease (TRCAD) and the following potential risk factors: (a) number of HLA mismatches between recipient and donor; (b) production of anti-HLA antibodies; (c) growth of lymphocytes infiltrating the graft; and (d) frequency of biopsy proven episodes of acute rejection. The study population consisted of 285 adult heart allograft recipients who were monitored over a period of two years or more. The results demonstrate a significant correlation between TRCAD, generation of anti-HLA class II antibodies and potential of lymphocytes infiltrating the graft to proliferate ex-vivo in medium containing IL-2. Humoral and cellular immune responses to HLA-DR antigens expressed by the graft seem to underlie the development of TRCAD. (C) 2003 Elsevier B.V. All rights reserved.